The patent suit for Affinitor, which was conducted by Novartis and Kwang Dong, was finally closed due to the plaintiff's withdrawal. As a result, Kwang Dong and Samyang Biopharm are able to market more actively.

According to the industry on the 26th, the lawsuit against the use patent of Afinitor, which has been filed since March last year due to Novartis' complaint, ended with the withdrawal of the plaintiff's complaint on the 19th. Novartis filed a complaint in January last year asking for cancellation of the Intellectual Property Trial and Appeal Board's claim for invalidation of the Afinitor patent filed by Kwang Dong.

Kwang Dong first filed a claim for invalidation of the patent in M